Ovid Therapeutics Past Earnings Performance
Past criteria checks 0/6
Ovid Therapeutics has been growing earnings at an average annual rate of 4.4%, while the Biotechs industry saw earnings growing at 17.7% annually. Revenues have been growing at an average rate of 4.9% per year.
Key information
4.4%
Earnings growth rate
22.1%
EPS growth rate
| Biotechs Industry Growth | -14.6% |
| Revenue growth rate | 4.9% |
| Return on equity | -59.6% |
| Net Margin | -13,362.2% |
| Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
Recent updates
Revenue & Expenses BreakdownBeta
How Ovid Therapeutics makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 0 | -52 | 31 | 29 |
| 30 Sep 23 | 0 | -49 | 29 | 24 |
| 30 Jun 23 | 0 | -49 | 30 | 25 |
| 31 Mar 23 | 0 | -51 | 31 | 23 |
| 31 Dec 22 | 2 | -54 | 32 | 25 |
| 30 Sep 22 | 1 | -68 | 33 | 37 |
| 30 Jun 22 | 1 | -66 | 32 | 36 |
| 31 Mar 22 | 1 | -67 | 32 | 39 |
| 31 Dec 21 | 208 | 120 | 37 | 47 |
| 30 Sep 21 | 214 | 123 | 39 | 46 |
| 30 Jun 21 | 221 | 117 | 40 | 57 |
| 31 Mar 21 | 221 | 110 | 41 | 65 |
| 31 Dec 20 | 13 | -81 | 31 | 63 |
| 30 Sep 20 | 7 | -76 | 25 | 59 |
| 30 Jun 20 | 0 | -76 | 23 | 54 |
| 31 Mar 20 | 0 | -67 | 20 | 47 |
| 31 Dec 19 | 0 | -60 | 19 | 42 |
| 30 Sep 19 | 0 | -56 | 19 | 39 |
| 30 Jun 19 | 0 | -53 | 18 | 36 |
| 31 Mar 19 | 0 | -53 | 19 | 35 |
| 31 Dec 18 | 0 | -52 | 19 | 34 |
| 30 Sep 18 | 0 | -50 | 19 | 32 |
| 30 Jun 18 | 0 | -46 | 18 | 29 |
| 31 Mar 18 | 0 | -44 | 17 | 27 |
| 31 Dec 17 | 0 | -65 | 15 | 50 |
| 30 Sep 17 | 0 | -61 | 14 | 47 |
| 30 Jun 17 | 0 | -58 | 14 | 44 |
| 31 Mar 17 | 0 | -53 | 13 | 40 |
| 31 Dec 16 | 0 | -22 | 13 | 10 |
| 30 Sep 16 | 0 | -18 | 12 | 2 |
| 31 Dec 15 | 0 | -13 | 7 | 7 |
Quality Earnings: 1OT is currently unprofitable.
Growing Profit Margin: 1OT is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 1OT is unprofitable, but has reduced losses over the past 5 years at a rate of 4.4% per year.
Accelerating Growth: Unable to compare 1OT's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 1OT is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-11.5%).
Return on Equity
High ROE: 1OT has a negative Return on Equity (-59.61%), as it is currently unprofitable.